TOI Q1 revenue $104.4M (+10.3% YoY); net loss $19.6M vs $19.9M; reaffirms FY2025 guidance

Oncology Institute, Inc.

2025-Q1 EPS reported -$0.21 revenue$104,406,000

Revenue $104.4M, up 10.3% YoY from $94.7M; gross profit $17.2M, up 44.1%.
Net loss $19.6M ($0.21/share) vs $19.9M ($0.22) prior year; Adjusted EBITDA -$5.1M vs -$10.9M.
Pharmacy & Dispensary segment revenue $49.3M, gross profit >$9M, grew >20% YoY; FFS growth 9% QoQ.
Added >100,000 capitated lives in Q1; new contracts in FL, NV, CA; fully-delegated agreement started March 1 in FL.
Closed $16.5M private placement; exchanged $4.1M convertible notes for preferred stock & warrants; cash $39.7M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.